CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

ClinicalTrials.gov ID: NCT02734862

Public ClinicalTrials.gov record NCT02734862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Study identification

NCT ID: NCT02734862
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Enrollment: 207 participants

Conditions and interventions

Conditions

Interventions

CD101 Drug
Caspofungin Drug
Fluconazole Drug
intravenous placebo Drug
oral placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 25, 2016
Primary completion: May 31, 2019
Completion: Jun 30, 2019
Last update posted: Dec 7, 2020

2016 – 2019

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35233	—
University of California - Davis	Davis	California	95817	—
University of Miami Miller School of Medicine	Miami	Florida	33136	—
Augusta University	Augusta	Georgia	30912	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
Harper University Hospital	Detroit	Michigan	48201	—
Henry Ford Health System	Detroit	Michigan	48202	—
William Beaumont Hospital	Royal Oak	Michigan	48073	—
University of Mississippi Medical Center	Jackson	Mississippi	39216	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Mercury Street Medical	Butte	Montana	59701	—
Albany Medical Center	Albany	New York	12208	—
Mercy Health - St. Vincent Medical Center - ID Clinical Research	Toledo	Ohio	43608	—
Reading Hospital and Medical Center	West Reading	Pennsylvania	19611	—
University of Texas Health Science Center at Houston	Houston	Texas	77030	—
Virginia Tech, Carillion School of Medicine	Roanoke	Virginia	24016	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02734862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 7, 2020 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02734862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →